Skip to content
‹ Back to IndustriesHealthcare

The University of Kansas Announces Grant Funding for Knee Imaging Biomarkers Acquired from Weight Bearing CT

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT imaging and the critical need for more sensitive and affordable imaging biomarkers.

Osteoarthritis (OA) is the most prevalent form of arthritis, and the knee is the most commonly affected weight-bearing joint. The high cost of clinical trials creates a barrier for effective treatment development. Therefore, introduction of more specific and sensitive biomarkers could help to advance therapeutic development by reducing the time and sample sizes required for clinical trials.

Proposed Outcomes

There is an urgent need for imaging biomarkers that allow for identification of the best time in which patients will respond to treatment, and a means to analyze the efficiency of interventions. Early studies demonstrated the diagnostic value of bilateral weight-bearing CT in identifying knee OA symptoms accurately, as well as the feasibility to detect meniscal tears not detected by non-weight bearing MRI.

The grant from NIAMS will fund a study to validate the proposed imaging biomarkers and begin the qualification process for more responsive OA imaging biomarkers acquired using low-dose, bilateral standing CT imaging. Substantial advantages are offered over traditional radiographic biomarkers, including increased responsiveness to temporal changes in the joints, and a better reflection of the symptoms and severity of the disease. Additionally, this research will determine the prognostic validity of standing CT findings for detecting progression and worsening pain in people who currently suffer from or are at risk for knee OA.

Long-Term Impact

With the support of NIAMS, this research holds promise to detect joint damage earlier, and accelerate the pace of scientific discovery and clinical trials. The continuing impact will be evident through a shift in knee joint imaging with an improved biomarkers for monitoring knee OA disease features. If the additional meniscal extrusions detected on bilateral standing CT are clinically relevant, then standing CT could improve identification of the most appropriate patients for clinical trials – those at risk of rapid OA progression. Successful completion will provide improved biomarkers that will help those who suffer from knee OA through making clinical trials more affordable and accelerating therapeutic improvement.

For more information on visualizing cartilage and menisci in the knee using standing CT arthrogram versus MRI, click here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

TheraPanacea's CEO says software, not hardware, will scale radiotherapy

TheraPanacea's CEO says software, not hardware, will scale radiotherapy

TheraPanacea CEO Nikos Paragios said at ASTRO 2026 in Boston that vendor-agnostic AI software like ART-Plan can raise radiotherapy throughput on existing machines. A February 2025 Lancet Oncology study puts the global linac shortfall at 30%, with 36 of 181 countries owning no linac, limiting how far software alone can go.

  • 01A February 2025 Lancet Oncology study found a global median Linac Shortage Index of 130, a 30% capacity shortfall, and 36 of 181 countries with no linac at all.
  • 02Bundled adaptive systems already exist: Varian’s Ethos won FDA clearance in February 2020 and RaySearch demoed automated replanning at ASTRO, but buyers still need to validate acceptability and sign-off workflows.

Oct 29, 2026

Berg Insight expects 160 million home medical monitors in care programs by 2030

Berg Insight expects 160 million home medical monitors in care programs by 2030

Prescribed connected home medical monitors are forecast to grow from 92.7 million in 2025 to 159.7 million by 2030. Fastest growth is in diabetes, remote ECG and medication compliance, spread across many suppliers. Berg and IoT Business News argue value depends on integrating data into workflows.

  • 01159.7 million prescribed home medical monitors expected by 2030, growing at 11.5 percent annually from 92.7 million in 2025.
  • 02Sleep therapy is the largest connected segment, followed by diabetes with 19.5 million connections at end of 2025, with fastest future growth in diabetes, remote ECG and medication compliance monitoring.
  • 03Clinical value increasingly depends on integrating data across devices into workflows: vendors combine hardware, software, analytics and interoperability with existing healthcare systems.

Oct 26, 2026

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc has bought Sohar Health, its first acquisition in nearly 20 years. Sohar's software finds and verifies a patient's insurance coverage from a name and birth date. Zocdoc wants that check to work across its Care Access Network, which lets insurers, consumer apps and AI tools embed Zocdoc's clinician search and scheduling on their own websites and apps.

  • 01After nearly 20 years without an acquisition, Zocdoc's first purchase is the insurance check that sits between a patient's search and a booked appointment.
  • 02For practices that pay Zocdoc per booking, the sharper question is how often coverage verified at booking matches what the front desk confirms at check-in.

Oct 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512